In This Issue

• New Services
• Recent Conference Presentations

Quick Links

• Cureline
• Cureline BioPathology
• Molecular Medicine Tri-Conference
• AACR Annual Meeting 2009
• Predictive Biomarker Sciences
• Aperio

Dear Colleague:

Cureline, a global biosample management company, is presenting our services at the upcoming conferences and would like to invite you to visit and discuss current and potential scientifically challenging tissue research projects with Cureline's management team:

- February 25-27, 2009 - Molecular Medicine TRI-Conference "Shaping Future Medicine" in San Francisco, California, Moscone North Convention Center. Find us at booth # 318.

- April 18-22, 2009 - AACR 100th Annual Meeting 2009 "Science, Synergy, and Success" in the Colorado Convention Center, Denver, Colorado. Find us at booth # 1006.

ALL x60

Olga Potapova, PhD
Founder and CEO

New Services by Cureline BioPathology LLC.

human tissue research from human tissue acquisition to comprehensive tissue analysis special staining methods in support of you research or clinical studies.

Our experienced team provides services in target Human RNA , DNA Panels">expression analysis and biomarker development, clinical assay development for IHC staining of human tissues, and antibody cross-reactivity studies under GLP conditions. One of the recently introduced services is custom tissue /cell slide scanning and analysis using Aperio digital imaging technology.

Recent Conference Presentations

"Translational Cancer Medicine Conference" in San Diego (January 27 - 29, 2009) Dr. Michael Bittner, Senior Investigator and Co-Director at the Computational Biology Division of the Translational Genomics Research Institute, presented

"Cellular Drug Response Dynamics Measured on Populations of Single Cells", a new technology developed by PBS-Bio (Predictive Biomarkers Sciences), one of the Cureline's' strategic alliance companies. The presentation discussed a method of assessing candidate oncology drugs that allows characterization of whether a population of cells responds to a drug in a way that:
1) shows molecular responses consistent with the expected mechanism;
2) shows the presence of processes that interfere with efficacy;
3) suggests that the addition of another drug would increase efficacy and
4) suggests that there are sensitive and resistant sub-populations within the set of cells being examined.